Cargando…

Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy

Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency...

Descripción completa

Detalles Bibliográficos
Autores principales: Zapatka, Marc, Tausch, Eugen, Öztürk, Selcen, Yosifov, Deyan Yordanov, Seiffert, Martina, Zenz, Thorsten, Schneider, Christof, Bloehdorn, Johannes, Döhner, Hartmut, Mertens, Daniel, Lichter, Peter, Stilgenbauer, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883533/
https://www.ncbi.nlm.nih.gov/pubmed/33691380
http://dx.doi.org/10.3324/haematol.2020.265777
_version_ 1784659950210908160
author Zapatka, Marc
Tausch, Eugen
Öztürk, Selcen
Yosifov, Deyan Yordanov
Seiffert, Martina
Zenz, Thorsten
Schneider, Christof
Bloehdorn, Johannes
Döhner, Hartmut
Mertens, Daniel
Lichter, Peter
Stilgenbauer, Stephan
author_facet Zapatka, Marc
Tausch, Eugen
Öztürk, Selcen
Yosifov, Deyan Yordanov
Seiffert, Martina
Zenz, Thorsten
Schneider, Christof
Bloehdorn, Johannes
Döhner, Hartmut
Mertens, Daniel
Lichter, Peter
Stilgenbauer, Stephan
author_sort Zapatka, Marc
collection PubMed
description Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency over time and assessing the underlying cancer cell fraction revealed highly distinct evolutionary patterns. Surprisingly, in long-term stable disease and in relapse after long-lasting clinical response to treatment, clonal shifts are minor. In contrast, in refractory disease major clonal shifts occur although there is little impact on leukemia cell counts. As this striking pattern in refractory cases is not linked to a strong contribution of known CLL driver genes, the evolution is mostly driven by treatment-induced selection of sub-clones, underlining the need for novel, non-genotoxic treatment regimens.
format Online
Article
Text
id pubmed-8883533
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-88835332022-03-18 Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy Zapatka, Marc Tausch, Eugen Öztürk, Selcen Yosifov, Deyan Yordanov Seiffert, Martina Zenz, Thorsten Schneider, Christof Bloehdorn, Johannes Döhner, Hartmut Mertens, Daniel Lichter, Peter Stilgenbauer, Stephan Haematologica Article Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency over time and assessing the underlying cancer cell fraction revealed highly distinct evolutionary patterns. Surprisingly, in long-term stable disease and in relapse after long-lasting clinical response to treatment, clonal shifts are minor. In contrast, in refractory disease major clonal shifts occur although there is little impact on leukemia cell counts. As this striking pattern in refractory cases is not linked to a strong contribution of known CLL driver genes, the evolution is mostly driven by treatment-induced selection of sub-clones, underlining the need for novel, non-genotoxic treatment regimens. Fondazione Ferrata Storti 2021-03-11 /pmc/articles/PMC8883533/ /pubmed/33691380 http://dx.doi.org/10.3324/haematol.2020.265777 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Zapatka, Marc
Tausch, Eugen
Öztürk, Selcen
Yosifov, Deyan Yordanov
Seiffert, Martina
Zenz, Thorsten
Schneider, Christof
Bloehdorn, Johannes
Döhner, Hartmut
Mertens, Daniel
Lichter, Peter
Stilgenbauer, Stephan
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
title Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
title_full Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
title_fullStr Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
title_full_unstemmed Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
title_short Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
title_sort clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883533/
https://www.ncbi.nlm.nih.gov/pubmed/33691380
http://dx.doi.org/10.3324/haematol.2020.265777
work_keys_str_mv AT zapatkamarc clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT tauscheugen clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT ozturkselcen clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT yosifovdeyanyordanov clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT seiffertmartina clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT zenzthorsten clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT schneiderchristof clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT bloehdornjohannes clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT dohnerhartmut clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT mertensdaniel clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT lichterpeter clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy
AT stilgenbauerstephan clonalevolutioninchroniclymphocyticleukemiaisscantinrelapsedbutacceleratedinrefractorycasesafterchemoimmunetherapy